Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.04M | 3.24M | 4.31M | 2.95M | 4.27M |
| Gross Profit | -2.04M | -3.24M | -4.31M | -2.95M | -4.27M |
| SG&A Expenses | 1.19M | 1.80M | 1.14M | 1.21M | 1.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23M | 5.04M | 5.45M | 4.16M | 5.67M |
| Operating Income | -3.23M | -5.04M | -5.45M | -4.16M | -5.67M |
| Income Before Tax | -3.27M | -4.94M | -5.34M | -3.96M | -4.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.27M | -4.94M | -5.34M | -3.96M | -4.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.27M | -4.94M | -5.34M | -3.96M | -4.46M |
| EBIT | -3.23M | -5.04M | -5.45M | -4.16M | -5.67M |
| EBITDA | -3.20M | -5.01M | -5.42M | -4.12M | -5.63M |
| EPS Basic | -0.32 | -0.49 | -0.53 | -0.39 | -0.44 |
| Normalized Basic EPS | -0.20 | -0.30 | -0.33 | -0.24 | -0.33 |
| EPS Diluted | -0.32 | -0.49 | -0.53 | -0.39 | -0.44 |
| Normalized Diluted EPS | -0.20 | -0.30 | -0.33 | -0.24 | -0.33 |
| Average Basic Shares Outstanding | 10.17M | 10.17M | 10.17M | 10.17M | 10.22M |
| Average Diluted Shares Outstanding | 10.17M | 10.17M | 10.17M | 10.17M | 10.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |